Identifying factors for pembrolizumab eligibility in head and neck cancer

In patients with a CPS of 20 or higher, pembrolizumab can be administered as first-line treatment, with favorable expected therapeutic effects.

Authors

Yorihisa Orita (ORCID: https://orcid.org/0000-0002-2803-9623)
Satoru Miyamaru (ORCID: https://orcid.org/0000-0003-1008-6904)
Kohei Nishimoto (ORCID: https://orcid.org/0000-0001-6287-5898)
Daizo Murakami

Institutions

Kumamoto University (JP)

Publication Details

Journal: Journal of Cancer Research and Clinical Oncology
Published: 2025-02-06
DOI: https://doi.org/10.1007/s00432-025-06121-0
Primary Topic: Cancer Immunotherapy and Biomarkers
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Identifying factors for pembrolizumab eligibility in head and neck cancer

Yorihisa Orita, Satoru Miyamaru, Kohei Nishimoto, Daizo Murakami

Feb 6, 2025

Journal of Cancer Research and Clinical Oncology

Cancer Immunotherapy and Biomarkers

article

Identifying factors for pembrolizumab eligibility in head and neck cancer

Yorihisa Orita, Satoru Miyamaru, Kohei Nishimoto, Daizo Murakami

February 6, 2025article en

Abstract

In patients with a CPS of 20 or higher, pembrolizumab can be administered as first-line treatment, with favorable expected therapeutic effects.

Journal of Cancer Research and Clinical OncologyVol. 151(2)

Kumamoto University (JP)

Good health and well-being

Openalex Percentile: Top 97%

Cancer Immunotherapy and Biomarkers

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Identifying factors for pembrolizumab eligibility in head and neck cancer — Yorihisa Orita, Satoru Miyamaru, et al. · Journal of Cancer Research and Clinical Oncology (2025) | TGRS Research Map | TGRS